[HTML][HTML] The utilization of single-cell sequencing technology in investigating the immune microenvironment of ccRCC
Y Liu, G Wu - Frontiers in Immunology, 2023 - frontiersin.org
The growth and advancement of ccRCC are strongly associated with the presence of
immune infiltration and the tumor microenvironment, comprising tumor cells, immune cells …
immune infiltration and the tumor microenvironment, comprising tumor cells, immune cells …
[HTML][HTML] Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis
Y Hu, S Liu, L Wang, Y Liu, D Zhang… - Frontiers in …, 2023 - frontiersin.org
Background Recent research has suggested that patients with metastatic non-small cell lung
cancer (mNSCLC) can achieve ongoing response after discontinuation of immune …
cancer (mNSCLC) can achieve ongoing response after discontinuation of immune …
Discontinuation of immune-oncology combinations due to immune-related adverse events in patients with advanced renal cancers
K Bekku, M Schmidinger, S Katayama… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: Patients with advanced renal cell carcinoma (aRCC) treated with immune-
oncology (IO) drugs may need to discontinue the treatment when severe immune-related …
oncology (IO) drugs may need to discontinue the treatment when severe immune-related …
[HTML][HTML] Toxicity-Induced Discontinuation of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer: 6-Year Experience from a Specialized Uro-Oncology …
S Rodler, C Aydogdu, I Brinkmann, E Berg, R Kopliku… - Cancers, 2024 - mdpi.com
Simple Summary This study analyzed patients with metastatic bladder cancer. A total of 108
patients received immunotherapy, but 11 had to stop their immunotherapy because of …
patients received immunotherapy, but 11 had to stop their immunotherapy because of …
[HTML][HTML] Immune checkpoint activity regulates polycystic kidney disease progression
EK Kleczko, DT Nguyen, KH Marsh, CD Bauer, AS Li… - JCI insight, 2023 - ncbi.nlm.nih.gov
Innate and adaptive immune cells modulate the severity of autosomal dominant polycystic
kidney disease (ADPKD), a common kidney disease with inadequate treatment options …
kidney disease (ADPKD), a common kidney disease with inadequate treatment options …
[HTML][HTML] Identification of a Methylation-Regulating Genes Prognostic Signature to Predict the Prognosis and Aid Immunotherapy of Clear Cell Renal Cell Carcinoma
L Zhang, Z Su, F Hong, L Wang - Frontiers in Cell and Developmental …, 2022 - frontiersin.org
Methylation is one of the most extensive modifications of biological macromolecules and
affects cell-fate determination, development, aging, and cancer. Several methylation …
affects cell-fate determination, development, aging, and cancer. Several methylation …
[HTML][HTML] Active Surveillance in Metastatic Renal Cell Carcinoma
N Beecroft, TD Gauntner, R Upadhyay… - Journal of Kidney …, 2024 - ncbi.nlm.nih.gov
Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with a variable clinical
course. While therapies for treatment of this condition have progressed, they are not without …
course. While therapies for treatment of this condition have progressed, they are not without …
[HTML][HTML] Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
Y Wang, H Wang, M Yi, Z Han, L Li - Frontiers in Oncology, 2022 - frontiersin.org
Background In this study, compared to sunitinib as one of the available treatment options,
we aimed to evaluate the cost-effectiveness of lenvatinib plus pembrolizumab or everolimus …
we aimed to evaluate the cost-effectiveness of lenvatinib plus pembrolizumab or everolimus …
[HTML][HTML] Evaluating the optimal duration of immunotherapy in kidney cancer
M Parikh, PN Lara - Kidney Cancer (Clifton, Va.), 2022 - ncbi.nlm.nih.gov
Immune checkpoint inhibitor (ICI) therapy has rapidly altered the landscape of treatment of
metastatic renal cell carcinoma (mRCC), resulting in significant improvements in outcomes …
metastatic renal cell carcinoma (mRCC), resulting in significant improvements in outcomes …
[HTML][HTML] KIDNEY CANCER
N Beecroft, TD Gauntner, R Upadhyay, SJ Wang… - jkcvhl.com
Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with a variable clinical
course. While therapies for treatment of this condition have progressed, they are not without …
course. While therapies for treatment of this condition have progressed, they are not without …